BEDFORD, Mass., September 23, 2021 – Vox Biomedical announced that it has received a new contract from the National Institute on Drug Abuse (NIDA) to continue the development of breath analyzer technology for the detection of marijuana and opioids at the point-of-measurement using a simple exhaled breath test.
In an earlier contract, the Vox team validated the ability of this technology to detect ∆9 Tetrahydrocannabinol (THC) in a controlled laboratory setting at McLean Hospital in Belmont, MA. The preliminary data has shown that THC can be detected in the exhaled breath of impaired human subjects at sub-nanogram concentrations.
This NIH contract will expand the clinical study from marijuana to other drugs including opioids. Vox Biomedical will acquire human subject data from marijuana smokers, while demonstrating that its technology can also detect opioids in exhaled breath of recent users.
Successful results will provide a strong basis for the commercialization of Vox Biomedical technology.
Vox Biomedical will offer a drug detection instrument for real time exhaled breath drug analysis to law enforcement agencies and workplaces. Vox Biomedical is collaborating with DRAPER, a leading research and development organization in Cambridge, MA to rapidly bring this instrument to the market.
Disclaimer: Research reported in this press release is supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R42DA049655. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Contact:
Arash Aslani
VP/GM
781-301-3893
info@voxbiomedical.com